Desde Boehringer Ingelheim le presentamos los resultados del ensayo de seguridad cardiovascular a largo plazo de Linagliptina (CARMELINA^®: Cardiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk)¹.

Referencias:

1. Rosenstock J et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2018 Nov 9. doi: 10.1001/jama.2018.18269